Cormorant Asset Management’s Coherus Oncology CHRS Stock Holding History

Cormorant Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-620,300	Closed	-$8.9M	–	55
2017 Q2	$8.9M	Hold	620,300	–	–	1.48%	22
2017 Q1	$13.1M	Buy	620,300 +101,210	+19%	+$2.49M	1.9%	20
2016 Q4	$14.6M	Sell	519,090 -57,016	-10%	-$1.6M	1.97%	16
2016 Q3	$15.4M	Hold	576,106	–	–	1.7%	21
2016 Q2	$9.73M	Buy	576,106 +6,976	+1%	+$131K	1.38%	25
2016 Q1	$12.1M	Hold	569,130	–	–	1.82%	20
2015 Q4	$13.1M	Hold	569,130	–	–	1.56%	23
2015 Q3	$11.4M	Hold	569,130	–	–	1.82%	17
2015 Q2	$16.4M	Buy	569,130 +350,000	+160%	+$8.85M	2.19%	15
2015 Q1	$6.7M	Sell	219,130 -3,070	-1%	-$79.3K	1.04%	30
2014 Q4	$3.63M	Buy	+222,200	New	+$3.13M	0.56%	42

Other funds holding CHRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cormorant Asset Management's CHRS Position: Q3 2017 in Review

Cormorant Asset Management sold out of Coherus Oncology (CHRS) in Q3 2017, closing a stake of 620,300 shares — an estimated $8.9M sold.

Cormorant Asset Management first reported a position in CHRS in Q4 2014 and held it in 11 quarters. The position peaked at $16.4M in Q2 2015. 93 funds tracked by Wall St. Rank hold CHRS as of Q3 2017.

Cormorant Asset Management reported no remaining Coherus Oncology position as of Q3 2017 after selling out during the quarter.
Cormorant Asset Management sold 620,300 Coherus Oncology shares in Q3 2017, an estimated $8.9M.
Cormorant Asset Management first reported a position in Coherus Oncology in Q4 2014 and held it in 11 quarters.
Cormorant Asset Management's Coherus Oncology position peaked at $16.4M in Q2 2015.
93 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2017.

Based on Cormorant Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.